Publication Details - Technical Help

1. OVERVIEW
2. TABLE OF CONTENTS
3. CONTACT INFO
4. TECHNICAL HELP

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

Kimberly Blackwell, MD
Research Funding – Abraxis Bioscience, LLC; Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline
Paid Consultant – Novartis Pharmaceuticals Corporation
Speaker’s Bureau – Novartis Pharmaceuticals Corporation, sanofi-aventis U.S.

PER Editorial Staff
No relevant relationships to disclose

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this online newsletter for FDA-approved dosing, indications, and warnings.

Commercial Support
An educational grant for this activity was provided by Novartis Oncology.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

• Microsoft Internet Explorer Downloads (Outside Source)
• Mozilla Firefox Product Page (Outside Source)

Macintosh Users Compatible Web browsers include Firefox (Outside Source) and Apple Safari (Outside Source)

Illustration

For hormone receptor–positive breast cancer, complex interactions between signaling pathways greatly affect tumor progression and bone health. Bone maintenance results from a delicate balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption, which are both tightly regulated through maturation and subsequent activation of osteoblast and osteoclast precursors. A decrease in circulating estrogen levels due to menopause or endocrine therapy leads to a rapid loss of bone mineral density and an increase in fracture risk, implicating estrogen in the regulation of bone formation. The estrogen signaling pathway is also thought to have substantial cross-talk with the HER2 receptor pathway. Preclinical data demonstrate that upregulation of HER2 might contribute to resistance to endocrine therapy in hormone receptor–positive breast cancer cells, suggesting that coadministration of endocrine therapy with HER2-targeted therapy might circumvent this resistance mechanism. Ongoing studies are examining this dual-inhibition strategy as well as strategies to prevent bone loss in patients with breast cancer.

Disclaimer

The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949–0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Cancer Summaries & Commentaries
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367–3400
Fax: (214) 367–3304
E–mail: editor@cancerlearning.com